Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Oncology

• Publication date

  2013-06-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2012.48.1390PMID 23630215PMCID PMC4881333
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)

  2012cited by this paper
• A comprehensive survey of Ras mutations in cancer.

  2012influential reference
• Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers

  2012influential reference
• Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

  2012cited by this paper
• Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

  2012cited by this paper
• Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer

  2012cited by this paper
• KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts).

  2012influential reference
• Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

  2011cited by this paper
• Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

  2010cited by this paper
• Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

  2010cited by this paper
• Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

  2010cited by this paper
• Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

  2010cited by this paper
• Analysis of second primary lung cancers in the SEER database.

  2010cited by this paper
• Conformational States of Human Rat Sarcoma (Ras) Protein Complexed with Its Natural Ligand GTP and Their Role for Effector Interaction and GTP Hydrolysis*

  2010cited by this paper
• Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

  2010cited by this paper
• Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer.

  2010cited by this paper
• Prognostic significance of alterations in KRAS isoforms KRAS‐4A/4B and KRAS mutations in colorectal carcinoma

  2009cited by this paper
• Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

  2008cited by this paper
• Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

  2008influential reference
• Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

  2008cited by this paper
• Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

  2008cited by this paper
• Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

  2008cited by this paper
• Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

  2006cited by this paper
• Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

  2006cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

  2004cited by this paper
• The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

  2004cited by this paper
• The risk of second primary tumors after resection of stage I nonsmall cell lung cancer.

  2003cited by this paper
• Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer.

  2002cited by this paper
• Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

  2001cited by this paper
• K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

  1999cited by this paper
• Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.

  1997cited by this paper
• K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.

  1990cited by this paper
• The ras oncogenes in human lung cancer.

  1990cited by this paper
• Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.

  1988cited by this paper
• The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation.

  1988cited by this paper
• Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes.

  1988cited by this paper
• Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.

  1987cited by this paper
• An Unidentified Virus which causes the Rapid Production of Tumours in Mice

  1964cited by this paper

• Advances in targeting KRAS mutations: A promising approach for the treatment of non-small cell lung cancer (Review)

  2026influential citation
• Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung Adenocarcinoma.

  2025cites this paper
• Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS.

  2025cites this paper
• Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study.

  2025cites this paper
• Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer

  2025cites this paper
• Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis

  2025cites this paper
• KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC

  2025cites this paper
• Targeted therapeutic options in early and metastatic NSCLC-overview

  2024cites this paper
• Real-World Evidence Study of Patients with KRAS-Mutated NSCLC in Finland

  2024cites this paper
• Single‐cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation

  2024cites this paper
• CRISPR/Cas-Mediated Knockdown of PD-L1 and KRAS in Lung Cancer Cells

  2024cites this paper
• Unveiling the role of KRAS in tumor immune microenvironment.

  2024cites this paper
• KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential

  2024cites this paper
• Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations

  2024cites this paper
• Association of Oncogene Driver Mutations with Recurrence and Survival in Stage I Nonsmall Cell Lung Cancer.

  2024cites this paper
• RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

  2024cites this paper
• KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia

  2024cites this paper
• Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.

  2024cites this paper
• Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential

  2024cites this paper
• Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy

  2024cites this paper
• Clinical characteristics, outcomes and prognostic factors in KRAS mutant lung cancers: experience from a tertiary care cancer center in India

  2024cites this paper
• Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors

  2024cites this paper
• STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.

  2024cites this paper
• Current perspectives of KRAS in non-small cell lung cancer.

  2024cites this paper
• Frequently mutated genes in predicting the relapse of stage I lung adenocarcinoma

  2023cites this paper
• Small molecular inhibitors for KRAS-mutant cancers

  2023cites this paper
• Fast, sensitive, and specific multiplexed single-molecule detection of circulating tumor DNA.

  2023cites this paper
• Response of PRIMPOL-Knockout Human Lung Adenocarcinoma A549 Cells to Genotoxic Stress

  2023cites this paper
• Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark

  2023cites this paper
• KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma.

  2023cites this paper
• Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data.

  2023cites this paper
• Molecular markers of metastatic disease in KRAS mutant lung adenocarcinoma.

  2023cites this paper
• Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.

  2023cites this paper
• An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health

  2023cites this paper
• Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2023cites this paper
• Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.

  2022cites this paper
• Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

  2022cites this paper
• Reflections on drug resistance to KRASG12C inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment.

  2022cites this paper
• Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

  2022cites this paper
• A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

  2022cites this paper
• KRAS mutated Non‐Small Lung Carcinoma: A Real World Context from the Indian subcontinent

  2022cites this paper
• RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma

  2022cites this paper
• Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer

  2022cites this paper
• 基于分子标志的非小细胞肺癌术后复发预测专家共识

  2022cites this paper
• Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma

  2022cites this paper
• Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes

  2022cites this paper
• The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia

  2022cites this paper
• Machine learning application in personalised lung cancer recurrence and survivability prediction

  2022cites this paper
• Updated Prognostic Factors in Localized NSCLC

  2022cites this paper
• Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner

  2022cites this paper
• Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment

  2022cites this paper
• KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population

  2022cites this paper
• Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies

  2022cites this paper
• Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer.

  2022cites this paper
• Atezolizumab in the first-line treatment of metastatic non-small cell lung cancer. Clinical experience of the drug application. Case report

  2022cites this paper
• A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in KRAS ‐mutant invasive non‐mucinous adenocarcinoma

  2022cites this paper
• Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation

  2022cites this paper
• The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

  2021cites this paper
• Targeting KRAS G12C mutation in lung adenocarcinoma.

  2021cites this paper
• Insights from prospective multi-omic profiling of lymphocytes in resected lung cancer.

  2021cites this paper
• KRAS Mutations in Squamous Cell Carcinomas of the Lung

  2021cites this paper
• Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer

  2021cites this paper
• Untangling the KRAS mutated lung cancer subsets and its therapeutic implications

  2021cites this paper
• Review on Colonrectal Cancer

  2021cites this paper
• Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience

  2021cites this paper
• Title: Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer

  2021cites this paper
• The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study

  2021cites this paper
• Driver gene alterations profiling of Chinese non‐small cell lung cancer and the effects of co‐occurring alterations on immunotherapy

  2021cites this paper
• Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

  2021cites this paper
• The Absence of Mutations in the Exon 2 KRAS Gene in Several Ethnic Groups in North Sumatra May Not the Main Factor for Lung Cancer

  2021cites this paper
• Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

  2021cites this paper
• Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice

  2021cites this paper
• Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

  2021cites this paper
• On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.

  2021cites this paper
• Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

  2021cites this paper
• Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers

  2021cites this paper
• The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation

  2021cites this paper
• Pulmonary Inflammation and KRAS Mutation in Lung Cancer.

  2021cites this paper
• Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

  2021cites this paper
• Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma

  2021cites this paper
• KRAS G12C-mutant non-small-cell lung cancer: biology, developmental therapeutics, and molecular testing.

  2021cites this paper
• Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.

  2021cites this paper
• The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review

  2021cites this paper
• Biomarker series: KRAS- A narrative review

  2021cites this paper
• RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.

  2021cites this paper
• Oxidative stress-mediated induction of pulmonary oncogenes, inflammatory, and apoptotic markers following time-course exposure to ethylene glycol monomethyl ether in rats

  2020cites this paper
• Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

  2020cites this paper
• Impact of somatic mutations on prognosis in resected non‐small‐cell lung cancer: The Japan Molecular Epidemiology for lung cancer study

  2020cites this paper
• Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma.

  2020cites this paper
• Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment

  2020cites this paper
• Coexisting EGFR and TP53 Mutations in Lung Adenocarcinoma Patients Are Associated With COMP and ITGB8 Upregulation and Poor Prognosis

  2020cites this paper
• Immunotherapy in oncogene addicted non-small cell lung cancer

  2020cites this paper
• Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.

  2020cites this paper
• Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

  2020cites this paper
• Corporate Medical Policy

  2020cites this paper
• The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA

  2020cites this paper
• Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy

  2020cites this paper
• Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer

  2020cites this paper
• Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis

  2020cites this paper
• The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.

  2020cites this paper